Publications

5600 Results

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Authors
M Smith;O Jegede;SS Parekh;C Hanson;F Kuhr;P Martin;B Till;M Crump;JP Leonard;JW Friedberg;B Kahl;T Witzig
Journal / Conference
Blood (2019) 134 (Supplement_1): 751, abst 623; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), oral
Year
2019
Research Committee(s)
Lymphoma
Study Number(s)
CTSU/E1411

Factors That Potentially Impact Lenalidomide/R-CHOP (R2-CHOP) Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

Authors
G Nowakowski;A Chiappella;F Hong;R Gascoyne;DW Scott;W Macon;RL King;JE Amengual;RF Little;JP Leonard;JW Friedberg;L Kostakoglu;W Jurczak;K Yamamoto;M Czuczman;J Russo;K Hudak;J Zhang;S Wade;T Witzig;BS Kahl;U Vitolo
Journal / Conference
Blood (2019) 134 (Supplement_1): 4092, abst 626; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), poster
Year
2019
Research Committee(s)
Lymphoma
Study Number(s)
CTSU/E1412

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup NCTN Study S1001

Authors
D Persky;H Li;D Stephens;SI Park;NL Bartlett;L Swinnen;P Barr;J Winegarden;L Constine;TJ Fitzgerald;JP Leonard;BS Kahl;M Leblanc;J Song;RI Fisher;L Rimsza;SM Smith;JW Friedberg
Journal / Conference
Blood (2019) 134 (Supplement_1): 349; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), oral
Year
2019
Research Committee(s)
Lymphoma
Study Number(s)
S1001

Intraclonal Heterogeneity Caused by Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: an Analysis of SWOG S0016

Authors
WR Burack;H Li;D Adlowitz;J Spence;L Rimsza;R Braziel;C Spier;M Kaminski;JP Leonard;RI Fisher;M Leblanc;SM Smith;JW Friedberg
Journal / Conference
Blood (2019) 134 (Supplement_1): 2771; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), poster
Year
2019
Research Committee(s)
Lymphoma
Study Number(s)
S0016

Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial

Authors
A Hay;S Assouline;R Walter;RF Little;A Moseley;G Sperling;A Im;J Foran;J Radich;M Fang;HP Erba;L Michaelis
Journal / Conference
Blood (2019) 134 (Supplement_1): 3905; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), poster
Year
2019
Research Committee(s)
Leukemia
Study Number(s)
S1612

SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia

Authors
A Advani;A Moseley;M Liedtke;M O'Donnell;I Aldoss;M Mims;K O'Dwyer;M Othus;HP Erba
Journal / Conference
Blood (2019) 134 (Supplement_1): 227; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), oral
Year
2019
Research Committee(s)
Leukemia
Study Number(s)
S1312

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Authors
E Pogosova-Agadjanyan;A Moseley;F Appelbaum;T Chauncey;I-M Chen;H Erba;J Godwin;I Jenkins;M Fang;M Huynh;K Kopecky;A List;J Naru;J Radich;E Stevens;B Willborg;C Willman;B Wood;Q Zhang;S Meshinchi;D Stirewalt
Journal / Conference
Blood (2019) 134 (Supplement_1): 2691; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), poster
Year
2019
Research Committee(s)
Leukemia
Study Number(s)
S0106, S0112, SWOG-9031, SWOG-9333

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Authors
T Shanafelt;XV Wang;N Kay;S O'Brien;J Barrientos;C Hanson;HP Erba;RM Stone;M Litzow;M Tallman
Journal / Conference
Blood (2018) 132 (Supplement 1): LBA-4; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), oral
Year
2019
Research Committee(s)
Leukemia
Study Number(s)
CTSU/E1912

Combined Treatment with Lenalidomide and Epoetin Alfa leads to Durable Responses in patients with Epo-refractory, Lower Risk Non-deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

Authors
A List;X Sun;A Verma;JM Bennett;K McGraw;L Nardelli;J Maciejewski;J Altman;P Cheema;D Claxton;R Komrokji;S Luger;RJ Mattison;T Wassenaar;A Artz;CA Schiffer;M Tallman
Journal / Conference
Blood (2019) 134 (Supplement_1): 842 (American Society of Hematology (Dec 7-10, 2019, Orlando, FL)), oral, abst. 637
Year
2019
Research Committee(s)
Leukemia
Study Number(s)
CTSU/E2905

"Many Views on Value" of National Cancer Institute-Sponsored Randomized Trials

Authors
V Nghiem;R Vaidya;D Hershman;M Leblanc;S Ramsey;CD Blanke;J Unger
Journal / Conference
Society for Medical Decision Making Annual Meeting (October 20-23, 2019, Portland, OR), poster
Year
2019
Research Committee(s)
Cancer Care Delivery